Peer-influenced content. Sources you trust. No registration required. This is HCN.
Renal & Urology News
New data suggests that intensifying neoadjuvant therapy with abiraterone or docetaxel could significantly improve outcomes in very high-risk prostate cancer patients. Explore the full findings to consider how this could impact your treatment approach.
Oncology, Medical September 19th 2023
Oncology News Central (ONC)
New data from the FLAURA2 trial suggests a promising but complex treatment landscape for EGFR-mutated advanced NSCLC. Physicians should weigh the significant PFS benefits against the increased risk of adverse events before considering this combination as a first-line treatment option.
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH